Bookmark
Forward
Explore Literature Results
QuickView for TAKL;jsessionid=40E22499564EAE7F71FA29AA19705F76;jsessionid=787005E39F3AFF5E382EC41A340AB170;jsessionid=C367D95CAF574A9239FE4295078310FA;jsessionid=ED732D6F8E2B55D44E4470C64FCAE073;jsessionid=369D0FFBC2D87636BB1B0994D6332FBD;jsessionid=86EE8D8B6B703E6EEBA3A5B918311149;jsessionid=49BA9F47674F5003A9EB16565D277BA0;jsessionid=64A2860A58E179D654B41B3CA32D5353;jsessionid=2AB6C358D8E10E0068BA3A3FA18269AB;jsessionid=05699B3389FF8E80336A84AE96404FF7;jsessionid=E7BCD54B9139C6D21C6204CF4FE7D307 (gene)
Most Relevant Literature
- Computational analysis predicts the Kaposi's sarcoma-associated herpesvirus tegument protein ORF63 t…
- Disruption of Prostaglandin E2 Signaling in Cancer-Associated Fibroblasts Limits Mammary Carcinoma G…
- Stability of varicella-zoster virus open reading frame 63.
- Varicella-zoster virus ORF63 inhibits apoptosis of primary human neurons.
- Regions of the varicella-zoster virus open reading frame 63 latency-associated protein important for…
Most Relevant Clinical Trials
There were no clinical trials for TAKL;jsessionid=40E22499564EAE7F71FA29AA19705F76;jsessionid=787005E39F3AFF5E382EC41A340AB170;jsessionid=C367D95CAF574A9239FE4295078310FA;jsessionid=ED732D6F8E2B55D44E4470C64FCAE073;jsessionid=369D0FFBC2D87636BB1B0994D6332FBD;jsessionid=86EE8D8B6B703E6EEBA3A5B918311149;jsessionid=49BA9F47674F5003A9EB16565D277BA0;jsessionid=64A2860A58E179D654B41B3CA32D5353;jsessionid=2AB6C358D8E10E0068BA3A3FA18269AB;jsessionid=05699B3389FF8E80336A84AE96404FF7;jsessionid=E7BCD54B9139C6D21C6204CF4FE7D307
Explore Clinical Trials Results
